Risk-stratification models for SMM
| References . | Risk factors . | Risk groups . | Progression risk . |
|---|---|---|---|
| 2 | BMPC >10%; serum M protein >30 | 0 = low risk; 1 = intermediate risk; 2 = high risk | 2-y progression rate (5-y TTP): low risk, 6% (15%); intermediate risk, 22% (43%); high risk: 45% (69%) |
| 15 | 95% aberrant BMPC (absence of CD19 and/or CD45 expression, overexpression of CD56, or weak expression of CD38); immunoparesis of the uninvolved immunoglobulins | 0 = low risk; 1 = intermediate risk; 2 = high risk | Median TTP (5-y progression rate): low risk, NR (4%); intermediate risk, 73 mo (46%); high risk, 23 mo (72%) |
| 12 | BMPC >10%, serum monoclonal protein >30; involved FLC/uninvolved FLCr >8 | 0 = low risk; 1 = intermediate risk; 2-3 = high risk | 2-y progression rate (5-y progression rate): low risk, 12% (25%); intermediate risk, 27% (51%); high risk, 52% (76%) |
| 17 | BMPC ≥40%; involved/uninvolved FLCr ≥50; serum albumin ≥3.5 g/dL | 0 = low risk; 1 = intermediate risk; 2-3 = high risk | 2-y rates of progression were 16%, 44%, and 81% |
| 9 | BMPC >20%; serum monoclonal protein >2 g/dL; involved/uninvolved FLCr >20 | 0 = low risk; 1 = intermediate risk; 2-3 = high risk | Median TTP (mo): low risk, 109.8; intermediate risk, 67.8; high risk, 29.2 |
| References . | Risk factors . | Risk groups . | Progression risk . |
|---|---|---|---|
| 2 | BMPC >10%; serum M protein >30 | 0 = low risk; 1 = intermediate risk; 2 = high risk | 2-y progression rate (5-y TTP): low risk, 6% (15%); intermediate risk, 22% (43%); high risk: 45% (69%) |
| 15 | 95% aberrant BMPC (absence of CD19 and/or CD45 expression, overexpression of CD56, or weak expression of CD38); immunoparesis of the uninvolved immunoglobulins | 0 = low risk; 1 = intermediate risk; 2 = high risk | Median TTP (5-y progression rate): low risk, NR (4%); intermediate risk, 73 mo (46%); high risk, 23 mo (72%) |
| 12 | BMPC >10%, serum monoclonal protein >30; involved FLC/uninvolved FLCr >8 | 0 = low risk; 1 = intermediate risk; 2-3 = high risk | 2-y progression rate (5-y progression rate): low risk, 12% (25%); intermediate risk, 27% (51%); high risk, 52% (76%) |
| 17 | BMPC ≥40%; involved/uninvolved FLCr ≥50; serum albumin ≥3.5 g/dL | 0 = low risk; 1 = intermediate risk; 2-3 = high risk | 2-y rates of progression were 16%, 44%, and 81% |
| 9 | BMPC >20%; serum monoclonal protein >2 g/dL; involved/uninvolved FLCr >20 | 0 = low risk; 1 = intermediate risk; 2-3 = high risk | Median TTP (mo): low risk, 109.8; intermediate risk, 67.8; high risk, 29.2 |
BMPC, bone marrow plasma cell percentage; FLCr, serum free light chain ratio; NR, not reported; TTP, time to progression.